Clinical Trial: Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07715279) titled 'Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression' on July 14.

Brief Summary: Calcific aortic valve stenosis (CAVS) is a condition in which the aortic valve progressively narrows and stiffens due to calcium deposition, eventually impairing blood flow from the heart to the body. No drug therapy has been proven to slow CAVS progression. Individuals with mild-to-moderate CAVS are managed with periodic monitoring until the stenosis becomes severe, at which point surgical or transcatheter valve replacement is the only treatment option. The goal of this clinical trial is to determine whether vericiguat, an oral s...